The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype
about
Pharmacological treatment of anxiety disorders: current treatments and future directionsLost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humansThe pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to ratsThe mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brainA study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brainEcstasy: are animal data consistent between species and can they translate to humans?Catechol-o-methyltransferase and 3,4-({+/-})-methylenedioxymethamphetamine toxicity.Age differences in (±) 3,4-methylenedioxymethamphetamine (MDMA)-induced conditioned taste aversions and monoaminergic levels.The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivativesCytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns.Interactions between recreational drugs and antiretroviral agents.Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy.Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.A developmental comparison of the neurobehavioral effects of ecstasy (MDMA)The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine.Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice.Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptorsMDMA 'ecstasy' increases cerebral cortical perfusion determined by bolus-tracking arterial spin labelling (btASL) MRIEcstasy (MDMA) and oral health.Impact of rat P450 genetic polymorphism on diazepam metabolism.Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation.Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions.Ecstasy-induced recurrent toxic hepatitis in a young adult.MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6.Effect of acute brain tyrosine depletion on MDMA-induced changes in brain 5-HT.Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions.The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy").Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine.Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR.Ecstasy and neurodegeneration.Ecstasy and neurodegeneration. Tablets often contain substances in addition to, or instead of, ecstasy...Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.MDMA-evoked changes in the binding of dopamine D(2) receptor ligands in striatum of rats with unilateral serotonin depletion.Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum.Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density.Effects of repeated low doses of MDMA on EEG activity and fluoro-jade B histochemistry.Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans.
P2860
Q26851461-DCFF28AC-74C5-4DCA-9AF2-045BE0D370CFQ26859367-2859FE9A-0570-4C64-A42E-F725FF037827Q28344876-FD6DADDD-B444-4871-BC7C-3F5029ED8FE2Q28346708-6DE9AB63-6DD0-497C-9829-28A3C2322D8DQ28366048-FFBC232E-F3BC-464B-94D5-7FB472AE8842Q31033315-561C6ECE-841A-4A34-9C28-688A45AE705AQ33554672-6B2743BF-0E4F-479B-A346-8C12CAD1695EQ34026981-D90F5410-1DFB-4C3B-A900-4B8283FDEF41Q34112933-32A17410-848D-4E69-993E-F8D295F19BDCQ34132390-20E94578-EF9D-4F66-8BA8-D83AF47558C2Q34564778-69D907B6-A79E-4329-BC87-9D2396F0F27BQ34874414-FE7F67E9-98EE-4ACA-90F8-AF53E5D61F6AQ34976260-1CFBB740-58A9-4859-9B79-1F28B039A132Q35026311-7F6CA4FC-5736-4ED7-BDC8-D48A891C2954Q35745285-F8295F25-9829-4300-ACE1-A8FFAD208253Q35851128-428D5945-D81C-417E-99FC-010FEC1EFF1BQ35986088-53650389-B90F-437C-AD44-D4D9BF7D17D3Q36012329-F28635CF-C689-43D2-9449-BDC49B7E755DQ36357993-8AD69055-C739-4C0D-867D-9CEA2EA0B227Q36965878-89AB4AC9-A1AA-489A-A9E7-9140792232D3Q37082483-8593D07C-E15E-45E3-884F-87B311E2D18CQ37581626-2F53F2C7-04ED-49B4-95EF-0AE2E7120BA2Q37789757-9D02A8F7-59B5-4EC8-8880-C29DDC24F933Q38048826-5020514B-CCEC-4715-8A5A-C837DC5236F9Q38559983-A5E2F95E-8AD1-4DE1-9C4F-6C56400FC581Q40140901-E67C8131-E065-4836-AD08-0A5A5A1CBB80Q40372241-AA39780B-49F1-4A4B-A46C-335BDE508DFDQ40530195-00E36A7E-3028-48B9-8C42-3E1DE8FDD29AQ40636462-3344E127-BF81-44E3-B580-83CD64DB9DF3Q42008895-F926448C-D399-43E9-B096-85FDA39291FEQ42261569-0244B0A0-E78F-467D-842E-A50819F0340DQ42275804-539F3895-0CEC-4DF2-A8D4-78761BCC7828Q43090371-537D0A7D-13DB-47C5-A990-ACC4368B809BQ43189245-F671B5A7-0F3A-46D7-ABB4-55B2339A00ACQ43201597-2427B0CF-E810-4CCA-87F2-8F0DB1AF3AB5Q43273690-2C6C621E-5609-47CE-B05B-AB18684712F3Q44028686-3B9E6622-25CB-40E4-83C2-7D099EE389FDQ44407124-19F27009-CB66-4D16-9B06-621630F917D5Q45149972-944B1130-AA3D-4A15-A09A-C7BE078F115EQ46013540-9135F50C-6237-4C5A-A567-5822434FB383
P2860
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
The hyperthermic and neurotoxi ...... 2D6 poor metabolizer phenotype
@ast
The hyperthermic and neurotoxi ...... 2D6 poor metabolizer phenotype
@en
type
label
The hyperthermic and neurotoxi ...... 2D6 poor metabolizer phenotype
@ast
The hyperthermic and neurotoxi ...... 2D6 poor metabolizer phenotype
@en
prefLabel
The hyperthermic and neurotoxi ...... 2D6 poor metabolizer phenotype
@ast
The hyperthermic and neurotoxi ...... 2D6 poor metabolizer phenotype
@en
P2093
P2860
P1476
The hyperthermic and neurotoxi ...... 2D6 poor metabolizer phenotype
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1995.TB15037.X
P407
P577
1995-08-01T00:00:00Z